Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Pharmacogenetic Testing
Interventions
Genecept Assay and G-DIG decision tool
Genetic
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions
decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay
Drug · Biological · Other + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Not listed No phase listed Observational

African-American Pharmacogenetics

NCT01408121
Conditions
Acute Coronary Syndrome
Interventions
Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Conditions
Head and Neck Cancer
Interventions
Southern blotting, TdT-mediated dUTP nick end labeling assay, gene expression analysis, protein expression analysis, flow cytometry, fluorescent antibody technique, immunoenzyme technique, immunohistochemistry staining method, immunologic technique
Genetic · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
3
States / cities
Nashville, Tennessee
Recruiting No phase listed Observational

Caris Chromoseq Data Collection

NCT07680868
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
Interventions
Caris Chromoseq
Diagnostic Test
Lead sponsor
Caris Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
Interventions
pharmacological study, laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more
Completed No phase listed Observational

Diet and Genetic Damage

NCT00340743
Conditions
Diet
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
Interventions
Systemic therapy, StrataNGS
Other · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Fragile X Syndrome
Interventions
Not listed
Lead sponsor
Esoterix Genetic Laboratories, LLC
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Westborough, Massachusetts
Conditions
Depression, Adverse Effects
Interventions
Genocept Assay
Genetic
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Conditions
Leukemia, Myelodysplastic Syndromes, Myeloproliferative Syndrome
Interventions
Genomic profiling
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
8
States / cities
Hartford, Connecticut • Portland, Maine • Boston, Massachusetts + 4 more
Conditions
Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma
Interventions
lopinavir, ritonavir, polymerase chain reaction, flow cytometry, enzyme-linked immunosorbent assay, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Breast Cancer
Interventions
letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
172
States / cities
Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more
Conditions
Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
Interventions
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
Biological · Device
Lead sponsor
Daniel Bauer
Other
Eligibility
13 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration, Survey Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 10 more
Conditions
Leukemia, Myelodysplastic Syndromes, Sarcoma
Interventions
clonality analysis, microsatellite instability analysis, mutation analysis
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
83
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 72 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03)

NCT06611540
Conditions
Cervical Carcinoma, Human Papillomavirus Infection
Interventions
Biospecimen Collection, Cervical Biopsy, Colposcopy, Electronic Health Record Review, Endocervical Curettage, Excision, HPV Self-Collection, Human Papillomavirus Test, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
11
States / cities
Atlanta, Georgia • Louisville, Kentucky • Ann Arbor, Michigan + 8 more
Conditions
Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, DNA methylation analysis, TdT-mediated dUTP nick end labeling assay, fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, breast duct lavage, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Dr. Susan Love Research Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
2
States / cities
Eureka, California • Santa Monica, California
Conditions
Breast Cancer, Cognitive Ability, General, Fatigue, Pain, Psychosocial Deprivation, Radiation Toxicity, Skin Abnormalities
Interventions
DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay, flow cytometry, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, assessment of therapy complications, quality-of-life assessment, 3-dimensional conformal radiation therapy, breast irradiation, external beam radiation therapy, hypofractionated radiation therapy, intensity-modulated radiation therapy, whole breast irradiation
Genetic · Other · Procedure + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland